Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV ... That's an annualized pace of $8.8 billion -- a significant drop from 2022 -- and it's likely to continue shrinking as Humira cedes market share.

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...

AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $47.94B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

IBM stock popped as Q4 earnings and revenue topped Wall Street estimates while 2025 revenue guidance came in above ...

In its earnings presentation, Tesla maintained its timeline for self-driving robotaxis. FSD is short for Full Self Driving, ...